Early Clinical Effect of Atorvastatin and Rosuvastatin in Patients with Coronary Heart Disease
Objective To investigate the difference of the early clinical effects of atorvastatin and rosuvastatin in the treatment of coronary heart disease(CHD).Methods A total of 74 CHD patients admitted to Peixian People's Hospital from June to December 2021 were selected as the study objects.They were divided into two groups,A and B,accord-ing to the coin toss,with 37 cases in each group.Group A and group B were treated with atorvastatin and rosuvastatin,respectively.Serum hypersensitive C-reactive protein,serum lipid levels,cardiac function and incidence of recurrent angina pectoris were compared between the two groups after treatment.Results After treatment,serum hypersensitive C-reactive protein,total cholesterol,left ventricular end-systolic diameter,triacylglycerol,left ventricular end-diastolic diameter and low density lipoprotein cholesterol in 2 groups were lower than before treatment,and the reduc-tion was more significant in group B,the differences were statistically significant(all P<0.05).Serum high density lipo-protein level(1.12±0.22)mmol/L and left ventricular ejection fraction(55.92±5.62)%in group B were higher than those in group A(1.02±0.14)mmol/L and(53.16±5.95)%,and the differences were statistically significant(t=-2.333,-2.051,both P<0.05).There was no significant difference in the incidence of recurrent angina pectoris between two groups(χ2=0.753,P>0.05).Conclusion Both atorvastatin and rosuvastatin are effective in the treatment of CHD,but rosuvastatin is more effective than atorvastatin.
AtorvastatinRosuvastatinCoronary heart diseaseHypersensitive C-reactive proteinBlood lipidCardiac function
NETL
NSTL
万方数据
